What you should know:
1. Phathom will develop and commercialize Takeda’s potassium competitive acid blocker, vonoprazan, in the U.S., Europe and Canada.
2. Frazier led a $90 million financing round supported by several other investors.
3. Phathom then took out a $50 million loan through Silicon Valley Bank to support developmental efforts.
More articles on gastroenterology:
CHI Franciscan to divest ASC, pay $2.5M to settle anticompetitive lawsuit: 5 things to know
Surgery Partners reports $417M in revenue & more — 10 ASC industry notes
As investors favor ASCs & offices, major skilled nursing operator splits segments
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
